BACKGROUND: (131)I-meta-iodobenzylguanidine ((131)I-MIBG) has been in therapeutic use since 1980s. Newer treatment modalities are emerging for neuroendocrine tumours (NETs) and chromaffin cell tumours (CCTs), but many of these do not yet have adequate long-term follow-up to determine their longer term efficacy and sequelae. METHODS: Fifty-eight patients with metastatic NETs and CCTs who had received (131)I-MIBG therapy between 2000 and 2011 were analysed. Survival and any long-term haematolog...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Sequelae and survivorship in patients treated with (131)I-MIBG therapy.
If you are the owner of this record, you can report an update to it here: Report update to this record